Zevra Therapeutics Stock Market Value
| ZVRA Stock | 8.15 0.06 0.73% |
| Symbol | Zevra |
Zevra Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zevra Therapeutics. If investors know Zevra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zevra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.28) | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets | Return On Equity |
The market value of Zevra Therapeutics is measured differently than its book value, which is the value of Zevra that is recorded on the company's balance sheet. Investors also form their own opinion of Zevra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Zevra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zevra Therapeutics' market value can be influenced by many factors that don't directly affect Zevra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zevra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zevra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zevra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Zevra Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Zevra Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Zevra Therapeutics.
| 12/25/2024 |
| 03/25/2025 |
If you would invest 0.00 in Zevra Therapeutics on December 25, 2024 and sell it all today you would earn a total of 0.00 from holding Zevra Therapeutics or generate 0.0% return on investment in Zevra Therapeutics over 90 days. Zevra Therapeutics is related to or competes with Transcode Therapeutics, Fortress Biotech, Akebia Ther, Reviva Pharmaceuticals, Monte Rosa, Pmv Pharmaceuticals, and Pharvaris. Zevra Therapeutics is entity of United States More
Zevra Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Zevra Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Zevra Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0078 | |||
| Maximum Drawdown | 14.76 | |||
| Value At Risk | (4.47) | |||
| Potential Upside | 4.66 |
Zevra Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zevra Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Zevra Therapeutics' standard deviation. In reality, there are many statistical measures that can use Zevra Therapeutics historical prices to predict the future Zevra Therapeutics' volatility.| Risk Adjusted Performance | 0.005 | |||
| Jensen Alpha | 0.0241 | |||
| Total Risk Alpha | 0.095 | |||
| Treynor Ratio | (0.01) |
Zevra Therapeutics Backtested Returns
Zevra Therapeutics shows Sharpe Ratio of -0.0152, which attests that the company had a -0.0152 % return per unit of risk over the last 3 months. Zevra Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Zevra Therapeutics' Standard Deviation of 2.72, insignificant market risk adjusted performance, and Mean Deviation of 2.07 to validate the risk estimate we provide. The firm maintains a market beta of 1.08, which attests to a somewhat significant risk relative to the market. Zevra Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Zevra Therapeutics is expected to follow. At this point, Zevra Therapeutics has a negative expected return of -0.0427%. Please make sure to check out Zevra Therapeutics' jensen alpha, as well as the relationship between the skewness and day typical price , to decide if Zevra Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.29 |
Weak reverse predictability
Zevra Therapeutics has weak reverse predictability. Overlapping area represents the amount of predictability between Zevra Therapeutics time series from 25th of December 2024 to 8th of February 2025 and 8th of February 2025 to 25th of March 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Zevra Therapeutics price movement. The serial correlation of -0.29 indicates that nearly 29.0% of current Zevra Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.29 | |
| Spearman Rank Test | -0.44 | |
| Residual Average | 0.0 | |
| Price Variance | 0.08 |
Zevra Therapeutics lagged returns against current returns
Autocorrelation, which is Zevra Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Zevra Therapeutics' stock expected returns. We can calculate the autocorrelation of Zevra Therapeutics returns to help us make a trade decision. For example, suppose you find that Zevra Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Zevra Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Zevra Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Zevra Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Zevra Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Zevra Therapeutics Lagged Returns
When evaluating Zevra Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Zevra Therapeutics stock have on its future price. Zevra Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Zevra Therapeutics autocorrelation shows the relationship between Zevra Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Zevra Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Zevra Therapeutics Correlation, Zevra Therapeutics Volatility and Zevra Therapeutics Alpha and Beta module to complement your research on Zevra Therapeutics. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Zevra Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.